David Nguyen, DO
Internal Medicine · Seminole, FLNPI 1174656151
Payments from drug & device makers
Across 229 payments — averaging $33.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$2K
- GSK$1K
- Johnson & Johnson$525
- Novo Nordisk$517
- Amgen$380
- plus $2K from 19 others
What the payments were for
- Food & beverage$7,707100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $1,708 |
| AbbVie | 42 | $1,533 |
| GSK | 27 | $1,325 |
| Johnson & Johnson | 13 | $525 |
| Novo Nordisk | 28 | $517 |
| Amgen(2 entities) | 17 | $380 |
| Lilly USA, LLC | 15 | $309 |
| Bayer | 9 | $227 |
| Pfizer | 7 | $191 |
| Idorsia Pharmaceuticals US Inc | 3 | $151 |
| Boehringer Ingelheim | 2 | $120 |
| Amarin Pharma, Inc. | 6 | $115 |
| Exact Sciences | 5 | $95 |
| RGH Enterprises LLC | 1 | $92 |
| Dynavax Technologies Corporation | 3 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Boston Scientific | 1 | $57 |
| Phathom Pharmaceuticals, Inc. | 1 | $51 |
| Novartis | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $27 |
| Cardiovascular Systems Inc. | 1 | $24 |
| Halozyme Inc | 1 | $18 |
| Medtronic | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,707 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $48,530 |
| JardianceEmpagliflozin | 43 | $44,089 |
| FarxigaDapagliflozin Propanediol | 28 | $43,510 |
| MounjaroTirzepatide | 32 | $38,772 |
| TrulicityDulaglutide | 23 | $36,577 |
| OzempicSemaglutide | 29 | $33,470 |
| ProliaDenosumab | 17 | $29,983 |
| EliquisApixaban | 19 | $22,074 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $19,607 |
| XareltoRivaroxaban | 18 | $17,265 |
| LinzessLinaclotide | 15 | $13,445 |
| JanuviaSitagliptin Phosphate | 16 | $10,019 |
| Atorvastatin Calcium | 213 | $2,936 |
| Levothyroxine Sodium | 278 | $2,607 |
| Glipizide ErGlipizide | 85 | $2,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $309 | $75,34955 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,708 | $63,11748 claims |
| GSKTrelegy Ellipta | $1,325 | $48,53033 claims |
| Boehringer IngelheimJardiance | $120 | $44,08943 claims |
| Novo NordiskOzempic | $517 | $33,47029 claims |
| AmgenProlia | $380 | $29,98317 claims |
| PfizerEliquis | $191 | $22,07419 claims |
| Johnson & JohnsonXarelto | $525 | $17,26518 claims |
| AbbVieLinzess | $1,533 | $13,44515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Seminole
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.